Neuroligin fragments as blood‐based biomarkers for early detection of Alzheimer's disease
Identifying changes in synaptic proteins in the blood of individuals with aMCI and early AD could be instrumental for earlier disease detection. Our findings reveal that blood levels of specific NLGN fragments are elevated in the prodromal and early stages of AD and correlate with key indicators of disease onset, particularly plasma levels of pTau. These results suggest that NLGN fragments could serve as a primary care screening test and be incorporated into a panel of early biomarkers of AD.
Authors
- Maxime Pinard
- Benoit Coulombe (ORCID: https://orcid.org/0000-0003-1702-0692)
- Jonathan Brouillette (ORCID: https://orcid.org/0000-0003-1058-1892)
- Frederic Calon
- Jean‐François Gagnon
- Esen Sokullu
- Milton Guilherme Forestieri Fernandes
Institutions
- Université du Québec à Montréal (CA)
- Hôpital du Sacré-Cœur de Montréal (CA)
- Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal (CA)
- Montreal Clinical Research Institute (CA)
- Université Laval (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_097403
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00